Neuren Pharmaceuticals Limited·Healthcare

Hyperion DeFi (NASDAQ: HYPD - Get Free Report) and Neuren Pharmaceuticals (OTCMKTS:NURPF - Get Free Report) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, valuation, earnings, analyst recommendations, profitability and risk. Valuation and Earnings This table compares Hyperion DeFi

Shares of Neuren Pharmaceuticals Limited (OTCMKTS:NURPF - Get Free Report) were down 13.5% during mid-day trading on Monday. The company traded as low as C$8.53 and last traded at C$8.53. Approximately 2,010 shares were traded during trading, an increase of 104% from the average daily volume of 987 shares. The stock had previously closed

Neuren Pharmaceuticals Limited (NURPF) Discusses Share Buyback Program, Financial Position, and Development Strategy for NNZ-2591 Transcript
Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. Its lead product is trofinetide, which is in Phase III clinical trial for the treatment of Rett syndrome, as well as has completed Phase II clinical trial to treat Fragile X syndrome. The company also develops NNZ-2591, which has completed Phase I clinical trial for the treatment of Phelan-McDermid, Angelman, Pitt Hopkins, and Prader-Will syndromes. In addition, it provides development services; and holds loan funded shares. The company was incorporated in 2001 and is based in Camberwell, Australia.
Healthcare
Biotechnology
8
2009-11-04
1.58